Supplementary Materials

The PDF file includes:

  • Fig. S1. In vitro binding specificity of MEDI5884.
  • Fig. S2. Effect of MEDI5884 on total-C and non–HDL-C in NHPs.
  • Fig. S3. PK profile of MEDI5884 in NHPs.
  • Fig. S4. Effect of combined EL and PCSK9 inhibition on ApoB and ApoA1 in NHPs.
  • Fig. S5. Study flow diagram describing clinical trial performed in healthy human participants.
  • Fig. S6. Effect of MEDI5884 on total-C and non–HDL-C in healthy human participants.
  • Fig. S7. PK profile of MEDI5884 in healthy human participants.
  • Fig. S8. Effect of MEDI5884 on VLDL/chylomicrons and IDL particles in healthy human participants.
  • Table S1. MEDI5884 does not inhibit lipoprotein lipase or hepatic lipase in vitro.
  • Table S2. Summary of PK characteristics of MEDI5884 in NHPs.
  • Table S3. Baseline characteristics of subjects enrolled in phase 1 clinical trial.
  • Table S4. Summary of adverse events reported during phase 1 clinical trial.
  • Table S5. Summary of PK characteristics of MEDI5884 in healthy human participants.
  • Legend for data file S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following: